FDA's Overreach on Compounded Peptides Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions BPC 157: Miracle Healing Peptide or Hidden Danger? Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling